



# Mapping Enzyme Activity on Tissue by Functional Mass Spectrometry Imaging

Brett R. Hamilton,\* David L. Marshall, Nicholas R. Casewell, Robert A. Harrison, Stephen J. Blanksby, and Eivind A. B. Undheim\*

**Abstract:** Enzymes are central components of most physiological processes, and are consequently implicated in various pathologies. High-resolution maps of enzyme activity within tissues therefore represent powerful tools for elucidating enzymatic functions in health and disease. Here, we present a novel mass spectrometry imaging (MSI) method for assaying the spatial distribution of enzymatic activity directly from tissue. MSI analysis of tissue sections exposed to phospholipid substrates produced high-resolution maps of phospholipase activity and specificity, which could subsequently be compared to histological images of the same section. Functional MSI thus represents a new and generalisable method for imaging biological activity *in situ*.

Enzymes are catalytic machines responsible for virtually every physiological process, and consequently, variations in enzyme abundance, activity, specificity, or efficacy are implicated in a wide range of pathologies.<sup>[1–5]</sup> Although changes in enzyme abundance and activity can be quantified by assaying homogenised tissue, such methods are vulnerable to averaging effects, which obscure highly localised changes. High-resolution spatially resolved assays of enzyme activity would therefore present a powerful tool for elucidating or diagnosing the causes of a range of diseases.<sup>[6]</sup> Targeted imaging of enzyme activity using chemically labelled probes<sup>[6,7]</sup> or substrates has been demonstrated;<sup>[8]</sup> however, no single imaging modality can routinely map the distribution of enzymes on tissue while simultaneously quantifying their catalytic efficacy and selectivity.

Mass spectrometry imaging (MSI)<sup>[9]</sup> partially solves this problem through the sensitive detection and high-resolution mapping of unlabelled analytes, such as spatial changes in metabolic profiles resulting from dysregulation of enzyme activity.<sup>[10]</sup> However, conventional MSI approaches yield complex spectra that are limited by incomplete structural elucidation of detected compounds, and an inability to link a specific metabolite to a unique biochemical pathway. This ambiguity makes MSI-based metabolomics an exhaustive approach for quantifying enzyme activity across tissues. Advanced MSI strategies that spatially resolve unique metabolites rely on the co-deposition of a reactive substrate during tissue preparation.<sup>[11,12]</sup> This presents an opportunity to move beyond merely the localization of biomolecules, to mapping enzymatic activity. Here, we introduce functional mass spectrometry imaging (fMSI) for measuring the spatial distribution of enzymatic activity across tissues. We used the venom glands of the brown forest cobra (*Naja subfulva*) as our model system because its venom is known to be rich in enzymatically active PLA<sub>2</sub>, making it ideal for the development of fMSI.<sup>[13]</sup> We demonstrate that fMSI assays are well suited to profiling phospholipase A2 (PLA<sub>2</sub>) activity, and can therefore describe the spatial distribution of active PLA<sub>2</sub> enzymes across histological sections. In principle, fMSI is transferrable to any MS-based enzymatic assay, and is thus applicable to the visualisation of many biological processes across different tissue types with micrometer-scale resolution.<sup>[14]</sup>

For the initial screening assay, separate solutions containing enzyme and substrate were mixed *in vitro* and infused

[\*] Dr. B. R. Hamilton  
Centre for Advanced Imaging, and Centre for Microscopy and Microanalysis, The University of Queensland  
Brisbane QLD 4072 (Australia)  
E-mail: b.hamilton@uq.edu.au  
Dr. D. L. Marshall, Prof. S. J. Blanksby  
Central Analytical Research Facility  
Institute for Future Environments  
Queensland University of Technology  
Brisbane QLD 4001 (Australia)  
Prof. N. R. Casewell, Prof. R. A. Harrison  
Centre for Snakebite Research & Interventions  
Liverpool School of Tropical Medicine  
Pembroke Place, Liverpool, L3 5QA (UK)  
Assoc. Prof. E. A. B. Undheim  
Centre for Biodiversity Dynamics  
Department of Biology  
Norwegian University of Science and Technology  
7491 Trondheim (Norway)


and  
Centre for Ecological and Evolutionary Synthesis  
Department of Bioscience  
The University of Oslo  
0316 Oslo (Norway)  
and  
Centre for Advanced Imaging, and Institute for Molecular Bioscience  
The University of Queensland  
Brisbane QLD 4072 (Australia)  
E-mail: eivind.a.b.undheim@ntnu.no

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:  
<https://doi.org/10.1002/anie.201911390>.

© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

directly into a mass spectrometer, which continually recorded the solution composition. To assay phospholipase activity, phosphatidylcholine (PC) substrates incorporating different fatty acids (FAs) on the glycerol backbone were selected. This enables discrimination between  $PLA_1$  and  $PLA_2$  activity, which facilitate selective ester hydrolysis at the *sn*-1 and *sn*-2 position, respectively.

As shown in Figure 1, the activity of porcine pancreatic  $PLA_2$  (pp $PLA_2$ ) was measured on a pair of regioisomeric glycerophospholipids incorporating palmitic and oleic acid, denoted PC 16:0/18:1 and PC 18:1/16:0 (the X:Y nomencla-




**Figure 1.** Mass-spectrometry-based enzyme assays are sensitive and powerful. Activity assay of porcine pancreatic  $PLA_2$  on phosphatidylcholine 34:1 isomers by nESI-MS. A) The temporal change in abundance of the substrate (PC 16:0/18:1, red) and LPC products. B) Averaged mass spectrum from the shaded area in (A). C) Depletion of PC 18:1/16:0 (red), and formation of LPCs. Averaging over the shaded area yields the mass spectrum shown in (D).

ture denotes the length and unsaturation of each FA<sup>[15]</sup>). A freshly prepared mixture of enzyme (in water) and substrate (in methanol) was infused directly into the mass spectrometer using a chip-based nano-electrospray ionization (nESI) source to eliminate sample carry-over. Extracted ion chromatograms shown in Figure 1A and 1C reveal a temporal depletion of the intact substrate and a concomitant increase in products arising from catalytic lipid hydrolysis. The rate of substrate depletion by  $PLA_2$  is dependent on the length and degree of unsaturation of the FA.<sup>[16]</sup> The major product observed upon mixing PC 16:0/18:1 with pp $PLA_2$  (Figure 1B) is lyso-phosphatidylcholine 16:0 (LPC 16:0, green trace), arising from liberation of oleic acid from the *sn*-2 position. The time-dependent increase of a second product ion at  $m/z$  522.4 (blue trace) was assigned to LPC 18:1. Based on MS/MS interrogation (Supporting Information, Figure S1), both species were assigned as LPCs arising from  $PLA_2$  activity on a mixture of isomers, rather than  $PLA_2$  and  $PLA_1$  activity on a unique substrate.<sup>[17,18]</sup> This hypothesis is consistent with the presence of PC 18:1/16:0 as an impurity in PC 16:0/18:1,<sup>[19]</sup> as confirmed by regiospecific tandem mass spectrometry experiments (Supporting Information, Figure S2).<sup>[20]</sup> A similar result was obtained for PC 18:1/16:0 in Figure 1C and Figure 1D, which demonstrates that  $PLA_2$  activity generates

LPC 18:1 as the major product (blue trace), but also LPC 16:0 arising from the alternate regioisomer. Furthermore, the activity of pp $PLA_2$  was trialed on various phospholipid substrates with similar results (e.g., PE 16:0/18:1, PC 16:0/22:6; Supporting Information, Figure S3), confirming the time-dependent conversion of the PC substrate into LPC products. These data demonstrate the feasibility of MS approaches to simultaneously measure substrate depletion and product generation in real time and with high specificity.

The selectivity of  $PLA_2$  activity in milked *N. subfulva* venom was screened against PC substrates to unambiguously identify the LPC products of phospholipase activity (Supporting Information, Figure S4). This revealed that MALDI induced some formation of LPC from the PC substrates, although at a much lower rate than observed by  $PLA_2$  activity. After validating the assay in vitro, glycerophospholipid substrates were applied to tissue sections in order to spatially map phospholipase activity by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry directly off the venom gland (i.e., fMSI). This experiment (Figure 2D–F) revealed that product ions arising from phospholipase activity ( $[LPC\ 16:1 + H]^+$ ,  $m/z$  494.3, yellow) can be found across the venom gland, but with some notable regional variation, such as lower abundance and even small patches lacking  $PLA_2$  activity in some posterior parts of the gland. In contrast, the distribution of intact substrate ( $[PC\ 16:1/16:1 + H]^+$ ,  $m/z$  730.6, blue) is largely restricted to regions outside the tissue perimeter, where we also only observed extremely low LPC signal corresponding to a low amount of MALDI-induced LPC formation. The identity of the major product ion in




**Figure 2.** fMSI of *N. subfulva* venom gland, showing the distribution of  $PLA_2$  activity against two different substrates. A) Optical image of a 7  $\mu$ m section of venom gland tissue. B) MALDI-MSI ion map. C) Averaged MALDI mass spectrum in the absence of lipid substrate. Application of PC 16:1/16:1 (D–F) or PC 15:0/18:1-d<sub>7</sub> (G–I)) with the MALDI matrix enables acquisition of fMSI ion maps of the substrate (blue) and  $PLA_2$  product (yellow) for each section ((E), (H)), along with their average spectra ((F), (I)). Scale bar: 2 mm.

Figure 2F was confirmed as enzyme-generated LPC 16:1 by an analogous experiment using a matrix-free tissue section and liquid extraction surface analysis coupled to a high-resolution tandem mass spectrometer (Supporting Information, Figure S5).

To ensure that the product signals were not from endogenous LPCs, the fMSI experiment was repeated using a deuterium-labelled substrate (PC 15:0/18:1-*d*<sub>7</sub>; Figure 2H). This experiment yielded significantly lower signal intensity than observed for PC 16:1/16:1, which is likely due to differences in the total amount of substrate deposited during sample preparation. Nevertheless, only the  $[M+H]^+$  ion corresponding to LPC 15:0 was observed ( $m/z$  482.3; Figure 2I), thus confirming that the products solely arise from PLA<sub>2</sub> activity. Products associated with other phospholipases were not observed from *N. subfulva* venom (Supporting Information, Figure S4). Moreover, in the absence of applied substrate (Figure 2B), no lipid signals were observed (Figure 2C). Finally, adding a PLA<sub>2</sub> inhibitor (Varespladib) prevented the formation of LPC 16:0 upon incubation of PC 16:0/18:1 with milked venom or liquid droplet extract from the venom gland of *N. subfulva* (Supporting Information, Figure S6). This was also the case in micro-dissected samples from the venom gland, where we also confirmed the presence of enzymatically active PLA<sub>2</sub> isoforms by bottom-up proteomics (Supporting Information, Figure S6). This finding confirms the preservation of enzyme activity throughout histological sample preparation, and is consistent with an even distribution of PLA<sub>2</sub> throughout the *N. subfulva* venom gland, as determined by shotgun proteomics of homogenized partitioned tissue sections (Supporting Information, Figure S7).

It is desirable to correlate the observed activity distribution with the spatial distributions of endogenous biomolecules, as well as histological features. The distribution of peptides and small proteins was therefore obtained by examining the same tissue section used for fMSI by conventional MSI (Figure 3). Venom PLA<sub>2</sub> proteins were not detected in *N. subfulva* venom gland tissue by MSI, possibly because of their high molecular weight and low abundance relative to other venom components. Nonetheless, this analysis (Figure 3C) revealed an intriguing non-uniform distribution of masses corresponding to three-finger toxins (3FTx) that has not previously been described. It is also worth noting that this heterogeneous distribution included a particular abundance of 3FTx in the same posterior region of the gland that showed little or no PLA<sub>2</sub> activity (Figure 2). The functional significance of these findings remains to be elucidated; however, similar heterogeneous toxin distributions have been found in the venom glands of other animals, reflecting functionally distinct venoms<sup>[21,22]</sup> or evolutionary constraints.<sup>[23]</sup> Following MSI acquisition and matrix removal, the tissue section can be stained using standard histological techniques (Figure 3A). Thus, fMSI is compatible with conventional MSI and histological workflows in biomarker discovery.

These results greatly improve our knowledge of the basic biology of the snake venom gland because they demonstrate for the first time that PLA<sub>2</sub> enzymes are functionally active



**Figure 3.** MSI and histology of the *N. subfulva* venom gland post-fMSI. A) Section of the *N. subfulva* venom gland after paraffin removal before substrate and matrix deposition (left); an H&E stain obtained following fMSI and MSI data acquisition and matrix removal (right). B) Averaged mass spectrum from MSI analysis of the same *N. subfulva* venom gland section post-fMSI acquisition, showing abundant signals from three-finger toxins known to be abundant in the venom. C) Spatial distribution of endogenous compounds in the *N. subfulva* venom gland, including three-finger toxins with possible cytotoxic and neurotoxic activities. Intensities of extracted ions ( $\pm 1$  Da) from normalized spectra are shown as heat maps across the tissue section. Scale bar: 2 mm.

during storage in the gland. The danger of venom enzymes to the glandular tissue is thought to be controlled by a variety of protein pre-prodomain structures and the expression of enzyme inhibitors.<sup>[24]</sup> This study suggests either that the glandular tissue is impervious to PLA<sub>2</sub> degradation, or that the inhibitory system for controlling PLA<sub>2</sub> bioactivity is readily disengaged, in this instance by histological processing. Either scenario raises fascinating questions regarding the co-evolution of snake venom PLA<sub>2</sub> and the factors that prevent the degradation of the venom gland in which they are stored.

There is a growing realisation of the versatility and power of MSI to map the distribution of specific biomolecules at micrometer-scale resolution across tissue sections.<sup>[9–12,14,25]</sup> Functional MSI adds to the repertoire of these capabilities by providing, for the first time, a method to map the spatial distribution of enzymatic activity. By applying substrate onto tissue sections, the type and distribution of active enzymes can be mapped through their catalytic products. Although this study used PLA<sub>2</sub> as the model enzyme, fMSI will be generally applicable to assaying the activity of different enzymes on any MSI platform, but particularly those equipped with high mass resolution and/or tandem mass spectrometry capabilities to increase confidence in product identification. Mass spectrometry is ideally suited to conducting simultaneous and comprehensive assays across multiple enzyme classes.<sup>[26]</sup> The activities of many enzymes can also be reproduced using mimic substrates that are more suitable for analysis by mass

spectrometry than native substrates because of their reduced molecular weight, greater solubility, and improved detectability.<sup>[27]</sup> Taken together, fMSI will undoubtedly yield new insight into enzyme biochemistry, and the numerous roles of enzymatic activity in health and disease.

### Acknowledgements

We thank Paul Rowley for snake husbandry and venom extractions, and Carsten Minten at Leica Microsystems for assistance with laser microdissections. This work was funded by the Australian Research Council (DE160101142 and DP160104025 to E.A.B.U., DP150101715 and DP190101486 to S.J.B., and LP140100832 to B.R.H.), the Norwegian Research Council (FRIPRO-YRT Fellowship no. 287462 to E.A.B.U.), the UK Medical Research Council (MR/L01839X/1 to N.R.C. and R.A.H.), and the Wellcome Trust and Royal Society (Sir Henry Dale Fellowship 200517/Z/16/Z to N.R.C.). Proteomic analyses were conducted at the Institute for Molecular Bioscience Proteomics Facility, The University of Queensland (UQ). MSI experiments were done at the Australian Microscopy & Microanalysis Research Facility, the Centre for Microscopy and Microanalysis, UQ. High mass resolution PLA<sub>2</sub> assays were conducted at the Central Analytical Research Facility (CARF), within the QUT Institute for Future Environments.

### Conflict of interest

The authors declare no conflict of interest.

**Keywords:** enzymes · functional assays · lipids · mass spectrometry imaging · PLA<sub>2</sub>

**How to cite:** *Angew. Chem. Int. Ed.* **2020**, *59*, 3855–3858  
*Angew. Chem.* **2020**, *132*, 3883–3886

- [1] M. R. Darragh, E. L. Schneider, J. Lou, P. J. Phojanakong, C. J. Farady, J. D. Marks, B. C. Hann, C. S. Craik, *Cancer Res.* **2010**, *70*, 1505–1512.
- [2] E. A. Dennis, J. Cao, Y. H. Hsu, V. Magrioti, G. Kokotos, *Chem. Rev.* **2011**, *111*, 6130–6185.
- [3] S. Kang, A. G. Bader, P. K. Vogt, *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 802–807.
- [4] M. M. Mohamed, B. F. Sloane, *Nat. Rev. Cancer* **2006**, *6*, 764–775.
- [5] E. Wiczorek, E. Jablonska, W. Wasowicz, E. Reszka, *Tumor Biol.* **2015**, *36*, 163–175.
- [6] M. Fonović, M. Bogoy, *Expert Rev. Proteomics* **2008**, *5*, 721–730.

- [7] J. W. Chang, R. E. Moellering, B. F. Cravatt, *Angew. Chem. Int. Ed.* **2012**, *51*, 966–970; *Angew. Chem.* **2012**, *124*, 990–994.
- [8] T. W. Bumpus, J. M. Baskin, *ACS Cent. Sci.* **2017**, *3*, 1070–1077.
- [9] R. M. Caprioli, T. B. Farmer, J. Gile, *Anal. Chem.* **1997**, *69*, 4751–4760.
- [10] M. R. L. Paine, B. L. J. Poad, G. B. Eijkel, D. L. Marshall, S. J. Blanksby, R. M. A. Heeren, S. R. Ellis, *Angew. Chem. Int. Ed.* **2018**, *57*, 10530–10534; *Angew. Chem.* **2018**, *130*, 10690–10694.
- [11] A. Bednařík, S. Bölsker, J. Soltwisch, K. Dreisewerd, *Angew. Chem. Int. Ed.* **2018**, *57*, 12092–12096; *Angew. Chem.* **2018**, *130*, 12268–12272.
- [12] F. Waldchen, B. Spengler, S. Heiles, *J. Am. Chem. Soc.* **2019**, *141*, 11816–11820.
- [13] L. P. Lauridsen, A. H. Laustsen, B. Lomonte, J. M. Gutierrez, *J. Proteomics* **2017**, *150*, 98–108.
- [14] M. Kompauer, S. Heiles, B. Spengler, *Nat. Methods* **2017**, *14*, 90–96.
- [15] G. Liebisch, J. A. Vizcaino, H. Kofeler, M. Trotzmüller, W. J. Griffiths, G. Schmitz, F. Spener, M. J. Wakelam, *J. Lipid Res.* **2013**, *54*, 1523–1530.
- [16] K. C. Batchu, S. Hänninen, S. K. Jha, M. Jeltsch, P. Somerharju, *Biochim. Biophys. Acta Mol. Cell. Biol. Lipids* **2016**, *1861*, 1597–1604.
- [17] X. Han, R. W. Gross, *J. Am. Chem. Soc.* **1996**, *118*, 451–457.
- [18] F.-F. Hsu, J. Turk, A. K. Thukkani, M. C. Messner, K. R. Wildsmith, D. A. Ford, *J. Mass Spectrom.* **2003**, *38*, 752–763.
- [19] R. L. Kozłowski, T. W. Mitchell, S. J. Blanksby, *Sci. Rep.* **2015**, *5*, 9243.
- [20] H. T. Pham, A. T. Maccarone, M. C. Thomas, J. L. Campbell, T. W. Mitchell, S. J. Blanksby, *Analyst* **2014**, *139*, 204–214.
- [21] S. Dutertre, A.-H. Jin, I. Vetter, B. Hamilton, K. Sunagar, V. Lavergne, V. Dutertre, B. G. Fry, A. Antunes, D. J. Venter, P. F. Alewood, R. J. Lewis, *Nat. Commun.* **2014**, *5*, 3521.
- [22] A. A. Walker, M. L. Mayhew, J. Jin, V. Herzig, E. A. B. Undheim, A. Sombke, B. G. Fry, D. J. Merritt, G. F. King, *Nat. Commun.* **2018**, *9*, 755.
- [23] E. A. B. Undheim, B. R. Hamilton, N. D. Kurniawan, G. Bowlay, B. W. Cribb, D. J. Merritt, B. G. Fry, G. F. King, D. J. Venter, *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 4026–4031.
- [24] S. C. Wagstaff, P. Favreau, O. Cheneval, G. D. Laing, M. C. Wilkinson, R. L. Miller, R. Stocklin, R. A. Harrison, *Biochem. Biophys. Res. Commun.* **2008**, *365*, 650–656.
- [25] S. R. Ellis, M. R. L. Paine, G. B. Eijkel, J. K. Pauling, P. Husen, M. W. Jervelund, M. Hermansson, C. S. Ejsing, R. M. A. Heeren, *Nat. Methods* **2018**, *15*, 515–518.
- [26] D. C. Sévin, T. Fuhrer, N. Zamboni, U. Sauer, *Nat. Methods* **2017**, *14*, 187–194.
- [27] H. Zhang, S. Maqsudi, A. Rainczuk, N. Duffield, J. Lawrence, F. M. Keane, D. Justa-Schuch, R. Geiss-Friedlander, M. D. Gorrell, A. N. Stephens, *FEBS J.* **2015**, *282*, 3737–3757.

Manuscript received: September 6, 2019

Revised manuscript received: October 29, 2019

Accepted manuscript online: December 18, 2019

Version of record online: January 23, 2020